Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • UBS Principal sells...

    UBS Principal sells 5.44 percent stake in Fortis Healthcare for Rs 443 crore

    Written by Ruby Khatun Khatun Published On 2018-05-04T10:30:57+05:30  |  Updated On 4 May 2018 10:30 AM IST
    UBS Principal sells 5.44 percent stake in Fortis Healthcare for Rs 443 crore

    New Delhi: UBS Principal Capital Asia offloaded 5.44 percent stake in Fortis Healthcare for over Rs 443 crore through an open market transaction.


    According to bulk deal data available with the National Stock Exchange (NSE), UBS shed a total of 2,82,31,975 shares, amounting to 5.44 per cent stake, of Fortis.



    The shares were sold on Rs 157 apiece, valuing the transaction at Rs 443.24 crore, the data showed.

    Meanwhile, York Asian Opportunities Investments Master Fund, York Asian Strategic Meteric Master, York Multi-Strategy Master Fund together picked up 2,82,35,492 shares of Fortis.


    Shares of Fortis closed at Rs 157.95 apiece on the NSE, down 0.6 percent from the previous close.


    Last week, Fortis had announced that its board will meet on May 10 to take a decision on the binding bids for the company as recommended by the expert advisory committee.


    The company has received binding offers from four entities - KKR-backed Radiant Life Care, Malaysian major IHH Healthcare, Manipal/TPG consortium and Munjal and Burman family offices.

    FortisFortis HealthcareNational Stock Exchangeopen market transactionsellsstakeUBS Principal
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok